Skip to content
OpenCapital
Get started

Anika Therapeutics ANIK US — PP&E (Net)

Other geography segments

IT
$1M—
GB
$29K—

Similar metrics at other companies

Alphatec Holdings logo
ATECUS — PP&E (Net)
$136.84M-5.7%
Merit Medical Systems logo
MMSIUS — PP&E (Net)
$300.59M+10.6%
Novanta logo
NOVTUS — PP&E (Net)
$23.93M-5.1%
Orthofix Medical Inc. logo
OFIXUS — PP&E (Net)
$111.04M-4.6%
Impinj, Inc. logo
PIUS — PP&E (Net)
$13.39M+1.0%
Coda Octopus Group, Inc. logo
CODAUS — PP&E (Net)
$2.01M—

Other financials

Income statement

See full
Revenue$29.6M+13.2%
Net income-$5.1M-3.8%

Balance sheet

See full
Cash & equivalents$41.0M-23.1%
Total debt$25.7M+1.2%
Total equity$133.9M-9.8%
Total assets$179.4M-5.9%

Cash flow

See full
Operating cash flow-$4.8M-3,628%
CapEx$1.4M-49.3%
Free cash flow-$6.3M-112%

Valuation

See full
Market cap$204.37M+31.6%
Enterprise value$189.09M+48.7%
P/S1.8×+0.1×

Profitability

See full
Net margin-9.8%-4.4pp
FCF margin0.9%—

Returns & leverage

See full
Return on equity-8%-3.4pp
Debt / equity0.2×0.0×
Current ratio4.5×-1.3×

Where this comes from

Reported directly by Anika Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.

The official record: Anika Therapeutics’s 10-K, filed March 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Anika Therapeutics's us — pp&e (net).

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Anika Therapeutics's US — PP&E (net)?
Anika Therapeutics (ANIK) reported US — PP&E (net) of $39.47M in Q4 2025.
How has Anika Therapeutics's US — PP&E (net) changed year-over-year?
Anika Therapeutics's US — PP&E (net) increased by 4.0% year-over-year, from $37.96M to $39.47M.
What does US — PP&E (net) mean?
This metric represents the net book value of tangible assets, such as manufacturing facilities and equipment, located within the United States segment after accumulated depreciation. It reflects the company's investment in domestic infrastructure required to support its orthopedic product development and supply chain operations. Monitoring this value helps evaluate the capital intensity and operational capacity of the domestic business unit.